Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.

Journal of viral hepatitis - 1 Jun 2020

Liu Zhenqiu, Mao Xianhua, Yu Kangkang, Suo Chen, Jin Li, Zhang Tiejun, Chen Xingdong

Abstract excerpt

Direct-acting antiviral (DAA) failure, which is mainly associated with the selection of resistance-associated substitutions (RASs), is not rare in HCV treatment. RAS data collected from published literature and RAS prevalence were integrated using meta-analysis. DAA-failure-associated RASs were identified by comparing their prevalence between DAA-failure and DAA-naïve patients. Prevalences of emerging RASs that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Substitution

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Prevalence

Share to Treatment Failure

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 32049405
DOI: 10.1111/jvh.13270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.PMID 32049405Read ↗

The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures.Semantic proximity Read ↗

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Semantic proximity Read ↗

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting AntiviralsSemantic proximity Read ↗

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.Semantic proximity Read ↗

World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents.Semantic proximity Read ↗

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.Semantic proximity Read ↗

Resistance Associated Mutations in HCV Patients Failing DAA Treatment.Semantic proximity Read ↗

Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.Semantic proximity Read ↗

NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey.Semantic proximity Read ↗

Treatment failure with DAA therapy: Importance of resistance.Semantic proximity Read ↗

A Database-Derived Global Overview of HCV Resistance-Associated Substitutions: Characterizing Genotypic, Regional, and Temporal Heterogeneity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.